Lekha Mikkilineni, MD, National Institutes of Health, Bethesda, MD, shares insight into the status of the chimeric antigen receptor (CAR) T-cell therapy field in multiple myeloma. She emphasizes the significant benefit that the introduction of CAR T-cell therapy has had, enabling deep and durable responses to be seen in relapsed/refractory patients, as well as the quality of life benefits that come from having a single infusion treatment. However, relapses still occur, particularly in patients with extramedullary disease or treatment induced BCMA-negative disease. Finding alternative targets for these patient subgroups needs to be a focus of future research. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
